Skip Ribbon Commands
Skip to main content


The Department of Nuclear Medicine and Molecular Imaging conducts both translational and clinical research, with the overall aims of improving both clinical care and management of patients. We have been awarded several grants from SingHealth and NMRC. We also have collaborative projects with other departments in the hospital and several pharmaceutical companies. 

Some of the main areas of research are as listed below:
  • Phase 0 trial of 18F-3-Fluoro-5-[(pyridin-3-yl)ethynyl] benzonitrile ([18F] FPEB), a PET imaging tracer for quantifying the cerebral distribution of Metabotropic Glutamate 5 receptors(mGluR5): To study radiochemical safety, biodistribution, tracer kinetics, and radiation dosimetry in the Asian population.
  • An Observational Study on Comparison of Quality of Life and Clinical Effects in Asian Patients Prepared with Thyroid Hormone Withdrawal or Recombinant Thyroid-Stimulating Hormone Administration for Remnant Ablation of Differentiated Thyroid Carcinoma (DTC).
  • “Is the partition model superior to empirical BSA method for delivery of Yittrium-90 resin microspheres in hepatocellular carcinoma”.
  • Selective internal radiation therapy (SIRT) versus Sorafenib for hepatocellullar carcinoma (AHCC06 trial), adopting an artery-specific SPECT/CT partition model dosimetry (click here).
  • Alpha-emitter Radium-223 dichloride for metastatic bone disease.
  • Pilot Study to Assess the Utility of Gallium-68 Labelled Prostate Specific Membrane Antigen (PSMA) Ligand PET/CT Imaging in Detecting Disease Recurrence in Prostate Cancer Patients with Biochemical Relapse.
  • Functional imaging with Gallium 68 DOTAPEPTIDE PET/CT and 131I-metaiodobenzylguanidine (MIBG) in order to determine feasibility of Peptide Receptor Radionuclide Therapy and MIBG therapy (combined therapy) in neuroblastoma. 
  • 18F-FMISO PET guided dose escalation in nasopharyngeal carcinoma – a feasibility and planning study.
  • Clinical Utility of Brain FDG PET in Neuroimaging.